EnglishEnglish
EnglishEnglishArabicArabicChinese (Simplified)Chinese (Simplified)FrenchFrenchGermanGermanHindiHindiPortuguesePortugueseRussianRussianSpanishSpanishSwahiliSwahili
  1. Home
  2. Evidence base
  3. Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry

Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry

Video URL

Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry

CGHE launched the TiP-HepC project on December 3rd at the International Viral Hepatitis Elimination Meeting (IVHEM). In the video on the right, Dr. Neil Gupta, Chief Technical Officer for the Coalition for Global Hepatitis Elimination, presents an abstract on the TiP-HepC project at IVHEM.

Contribute cases to TiP-HepC registry here

Background

Hepatitis C virus (HepC) antenatal screening is now recommended in the US and is increasingly the standard of care globally. However, there are no current interventions to reduce perinatal HepC transmission. Virologic suppression via the use of direct-acting antiviral (DAA) medications during pregnancy may reduce risk of mother-to-child HepC transmission, but there is very limited data regarding the safety and efficacy profile of DAAs for mother-infant pairs and off-label use of DAAs is determined on a case-by-case basis.

The Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry project is an initiative of the Coalition for Global Hepatitis Elimination (CGHE) at the Taskforce for Global Health and supported by the Centers for Disease Control and Prevention. 

Request for Collaboration

CGHE is seeking partners and collaborators for the TiP-HepC project to:

  • Contribute existing data on outcomes of mothers and infants exposed to DAA medications in pregnancy
  • Provide ideas, support, or case enrollment for a prospective registry to document outcomes of mothers and infants exposed to DAA medications in pregnancy
  • Join a “Community of Practice” to learn about current evidence and efforts in the treatment of HepC for pregnancy women

For questions contact:

Dr. Neil Gupta, Coalition for Global Hepatitis Elimination, ngupta-consultant [at] taskforce.org

 

Project Goal and Objectives

Project Goal

The goal of the TiP-HepC project is to consolidate and leverage existing data and engage a community of practice among relevant stakeholders to prospectively inform appropriate decision-making for HepC treatment in pregnancy.

Project Objectives

The objectives of the TiP-HepC project are to:

  1. Compile the existing knowledge, evidence, and initiatives related to HepC treatment in pregnancy. This includes sharing, aggregation, and analysis of existing data within HepC treatment programs globally demonstrating outcomes of mother-infant pairs exposed to DAA treatment during pregnancy or breastfeeding as a result of either intentional treatment or incidental exposures. 
  2. Plan prospective data sharing through a multi-country safety and effectiveness registry for mother-infant pairs exposed to DAAs.  No current standardized or unified registry exists to monitor mother-infant outcomes following exposure to DAAs. 
  3. Build a community of practice and advocacy coalition dedicated to treatment for HepC in pregnant women.  CGHE will develop an online knowledge hub and convene stakeholders using the knowledge generated through this project and profiling other efforts in the field. 

Submit Cases to the TiP-HepC Registry

Contribute existing data on outcomes of mothers and infants exposed to DAA medications in pregnancy by submitting to the Treatment in Pregnancy for Hepatitis C (TiP-HepC) Clinical Case Registry by clicking here.

Explore the TiP-Hep C Evidence Base

The evidence base was developed using rigorous review methods for the identification and quality assessment of eligible systematic reviews and guideline and policy documents. Explore it by clicking here.

Read an overview of the evidence base here.

Evidence Briefs

The purpose of these evidence briefs is to provide consolidated and updated information from the TiP-HepC registry regarding outcomes following exposure of directacting antiviral (DAA) medications in pregnant individuals with chronic hepatitis C virus (HCV) infection. They are intended to inform joint decision making by patients and providers for the optimal management of HCV infection during pregnancy.

 

Read the most recent evidence brief (No. 2) here.

(TiP-HepC Registry Evidence Brief No. 1 is available here)

Community of Practice

The Coalition has convened a TiP-HepC Community of Practice through a three-part webinar series focused on 1) the challenges of linkage and treatment for hepatitis C in pregnancy, 2) practical strategies and best practices to improve linkage to care and treatment, and 3) research needs to improve clinical practice and treatment coverage for pregnant persons.

This webinar series will brings together clinicians, academics, researchers, advocates, professional societies, regulatory agencies and industry representatives to align on best practices to improve treatment for HCV in pregnancy. 

You can view the webinar presentations and recordings here:

Part One- Challenges in HCV Linkage and Treatment in Pregnancy

Part Two- HepC in Pregnancy: Strategies to Improve Linkage to Care and Treatment

Part Three- Actions and Recommendations to Improve HCV Linkage and Treatment in Pregnancy

 

Last day updated 08 Nov 2023
Pregnant woman

Contribute data to TiP-HepC registry

The TiP-HepC registry is collecting retrospective data on the outcomes of mother– infant pairs exposed to DAAs during pregnancy in routine clinical practice will be solicited and collected from participating clinical providers, health-care facilities, HCV treatment programmes, and other clinical practices worldwide. 

Submit or upload cases here

Past webinars